U.K. Seeks Flexible Drug Pricing; NICE Becomes Flexible On Value
The British government and pharmaceutical industry are negotiating a pricing system that allows the National Health Service to pay more for a drug as its value is demonstrated in clinical practice
You may also be interested in...
In recent years, it has become standard practice for marketers of pharmaceutical and biotechnology products to offer a whole host of wraparound services to bolster the value proposition of their brands. Why not sell them?
Having called for a public debate on how the United Kingdom values and provides access to new medicines, the Association of the British Pharmaceutical Industry is organizing to make it happen
The U.K. National Health Service could save approximately £310 million in branded drug costs in 2009 under a preliminary agreement between the government and the pharmaceutical industry